Clene Nanomedicine, Inc. — Form D
Clene Nanomedicine, Inc. of SALT LAKE CITY, UT, a company, filed a Form D exempt-offering notice with the SEC on 2020-08-24. The offering totals $46.2M, of which $42.5M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2020-08-24
- Form: D
- Accession: 0001817741-20-000002
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $46.2M
- Amount sold: $42.5M
- Remaining: $3.6M
- Minimum investment: $10K
- Investors: 61
- Date of first sale: 2020-08-10
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-373923
Issuer
- Name: Clene Nanomedicine, Inc.
- CIK: 0001817741
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Address: 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY, UT, 84121
- Phone: 801-676-9695
Officers, directors & promoters (10)
| Name | Role | Location |
|---|
| Rob Etherington | Director | Salt Lake City, UT |
| Robert Gay | Director | Salt Lake City, UT |
| Shalom Jacobovitz | Director | Salt Lake City, UT |
| David Lisonbee | Director | Salt Lake City, UT |
| Alison Mosca | Director | Salt Lake City, UT |
| John Stevens | Director | New York, NY |
| Reed Wilcox | Director | Salt Lake City, UT |
| Chad Young | Director | Salt Lake City, UT |
| Rob Etherington | Executive Officer | Salt Lake City, UT |
| Ryan Lund | Director | Salt Lake City, UT |
Other filings by this issuer (1)
More